Local drug delivery system: Inhibition of inflammatory angiogenesis in a murine sponge model by dexamethasone-loaded polyurethane implants

Journal of Pharmaceutical Sciences

Volumn 100, Issue 7, 2011, Pages 2886-2895

  Moura, Sandra A L ^a   Lima, Luiza Dias C ^b   Andrade, Sílvia Passos ^b   Silva Cunha Junior, Armando Da ^b   Órefice, Rodrigo L ^b   Ayres, Eliane ^b   Da Silva, Gisele Rodrigues ^c  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Federal University of São Joãodel Rei   (Brazil)

Author keywords

Biodegradable polymers; Biomaterials; Controlled release delivery; Implants; Inflammatory angiogenesis; Local drug delivery system; Murine sponge model; Polymeric drug delivery system; Polyurethane; Targeted drug delivery

Indexed keywords

COLLAGEN; DEXAMETHASONE ACETATE; GLUCOCORTICOID; HAPTOGLOBIN; MYELOPEROXIDASE; N ACETYL BETA GLUCOSAMINIDASE; POLYURETHAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; FEMALE; FIBROSIS; HEMOGLOBIN ANALYSIS; HISTOLOGY; IMPLANT; INFLAMMATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; QUALITATIVE ANALYSIS; SPONGE (PORIFERA); SUBCUTANEOUS TISSUE; TISSUE GROWTH;

EID: 79955615204     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22497     Document Type: Article

References (51)

1. Folkman J, Ingber DE. 1987. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 206:374-383.
2. Cindy S, Mark L, Daniel WH, Frank B. 2007. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 275:71-78.
3. Buttgereit F, Saag KG, Cutolo M, da Silva JA, Bijlsma JW. 2005. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: Focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 34:14-21.
4. Barnes PJ. 1998. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci (Lond) 94(6):557-572.
5. Schoepe S, Schäcke H, May E, Asadullah K. 2006. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 15(6):406-420.
6. Gera C, Vij AS. 2009. Glucocorticoid-induced osteoporosis: Unawareness or negligence in India? Int J Rheum Dis 12(3):230-233.
7. Macfarlane DP, Forbes S, Walker BR. 2008. Glucocorticoids and fatty acid metabolism in humans: Fuelling fat redistribution in the metabolic syndrome. J Endocrinol 197(2):189-204.
8. Peeke PM, Chrousos GP. 1995. Hypercortisolism and obesity. Ann N Y Acad Sci 29(771):665-676.
9. De Nicola AF, Ferrini M, Gonzalez SL, Gonzalez DMC, Grillo CA, Piroli G, Saravia F, de Kloet ER. 1998. Regulation of gene expression by corticoid hormones in the brain and spinal cord. J Steroid Biochem Mol Biol 65(1-6):253-272.
10. Hickey T, Kreutzer D, Burgess DJ, Moussy F. 2002. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res 61:180-187.
11. da Silva GR, Fialho SL, Siqueira RC, Jorge R, Silva-Cunha AJ. 2010. Implants as drug delivery devices for the treatment of eye diseases. Braz J Pharm Sci 46(3):585-595.
12. Bourges JL, Bloquel C, Thomas A, Froussart F, Bochot A, Azan F, Gurny R, Benezra D, Behar-Cohen F. 2006. Intra-ocular implants for extended drug delivery: Therapeutic applications. Adv Drug Deliv Rev 58:1182-1202.
13. Yasukawa T, Ogura Y, Sakurai E, Tabata Y, Kimura H. 2005. Intraocular sustained drug delivery using implantable polymeric devices. Adv Drug Deliv Rev 57:2033-2046.
14. Dong X, Chen N, Xie L, Wang S. 2006. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal drug delivery system of all-trans retinoic acid. Retina 26:210-213.
15. Dong W, Scott CM, Xin-Ming L, Brian A, Xu SW, Steven RG. 2007. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther 9(1):1-9.
16. Sande PH, Fernandez DC, Aldana Marcos HJ, Chianelli MS, Aisemberg J, Silberman DM, Sáenz DA, Rosenstein RE. 2008. Therapeutic effect of melatonin in experimental uveitis. Am J Pathol 173(6):1702-1713.
17. Mruthyunjaya P, Khalatbari D, Yang P, Stinnett S, Tano R, Ashton P, Guo H, Nazzaro M, Jaffe GJ. 2006. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch Ophthalmol 124(7):1012-1018.
18. Sakurai E, Nozaki M, Okabe K, Kunou N, Kimura H, Ogura Y. 2003. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest Ophthalmol Vis Sci 44(11):4845-4852.
19. Knedla A, Riepl B, Lefèvre S, Kistella S, Grifka J, Straub RH, Gay S, Schölmerich J, Müller-Ladner U, Neumann E. 2009. The therapeutic use of osmotic minipumps in the severe combined immunodeficiency (SCID) mouse model for rheumatoid arthritis. Ann Rheum Dis 68(1):124-129.
20. da Silva GR, Ayres E, Moura SAL, Cara DC, Oréfice RL, Silva-Cunha AJ. 2009. Controlled release of dexamethasone acetate from biodegradable and biocompatible polyurethane and polyurethane nanocomposite. J Drug Target 17(5):374-383.
21. da Silva GR, Silva-Cunha A, Behar-Cohen F, Ayres E, Oréfice RL. 2010. Biodegradation of polyurethanes and nanocomposites to non-cytotoxic degradation products. Polym Degrad Stab 95(4):491-499.
22. Yasukawa T, Kimura H, Tabata Y, Ogura Y. 2001. Biodegradable sclera plugs for vitreoretinal drug delivery. Adv Drug Deliv Rev 52:25-36.
23. Kunou N, Ogura Y, Hashizoe M, Honda Y, Hyon S, Ikada Y. 1995. Controlled intra-ocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J. Control Release 37:143-150.
24. Mendes JB, Rocha MA, Araújo FA, Moura SA, Ferreira MA, Andrade SP. 2009. Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice. Microvasc Res 78(3):265-271.
25. Moura SAL, Ferreira MAND, Andrade SP, Reis MLC, Noviello ML, Cara DC. 2009. Brazilian green propolis inhibits inflammatory angiogenesis in a murine sponge model. Evid Based Complement Alternat Med 197:2-7.
26. Andrade SP, Machado RDP, Teixeira AS, Belo AV, Tarso AM, Beraldo WT. 1997. Sponge-induced angiogenesis in mice and the pharmacological reactivity of the neovasculature quantitated by a fluorimetric method. Microvasc Res 54: 253-261.
27. Andrade SP, Bakle YS, Hart I, Piper PJ. 1992. Effects of tumor cells on angiogenesis and vasoconstrictor responses in sponge implants in mice. Br J Cancer 66:821-826.
28. Ayres E, Oréfice RL, Yoshida MI. 2007. Phase morphology of hydrolysable polyurethanes derived from aqueous dispersions. Eur Polym J 43:3510-3521.
29. Bempong DK. 2007. Dexamethasone acetate. In The United States Pharmacopeia. 30th ed. Rockville: United States Pharmacopeial Convention, p 1887.
30. Einmahl S, Zignani M, Varesio E, Heller J, Veuthey JL, Tabatabay C, Gurny R. 1999. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Int J Pharm 185:189-198.
31. Fialho SL, Behar-Cohen F, Silva-Cunha A. 2009. Dexamethasone-loaded poly(ε-caprolactone) intravitreal implants: A pilot study. Eur J Pharm Biopharm 68(3):637-646.
32. Drabkin DL, Austin JH. 1935. Preparations from washed blood cells: Nitric oxide hemoglobin and sulphemoglobin. J Biol Chem 112:51-56.
33. Ferreira MA, Barcelos LS, Teixeira MM, Bakhle YS, Andrade SP. 2007. Tumor growth, angiogenesis and inflammation in mice lacking receptors for platelet activating factor (PAF). Life Sci 81:210-217.
34. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY. 2004. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114:438-446.
35. Campos PP, Bakhle YS, Andrade SP. 2008. Mechanisms of wound healing responses in lupus-prone New Zealand White mouse strain. Wound Repair Regen 16:416-424.
36. Deryugina EI, Quigley JP. 2010. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions. Biochim Biophys Acta 1803(1):103-120.
37. Szekanecz Z, Besenyei T, Paragh G, Koch AE. 2009. Angiogenesis in rheumatoid arthritis. Autoimmunity 42(7):563-573.
38. Szekanecz Z, Koch AE. 2009. Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 51(1):1-7.
39. Hori Y, Hu DE, Yasui T, Smither RL, Gresham GA, Fan TD. 1996. Differential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implants. Br J Pharmacol 118:1584-1591.
40. Araújo FA, Rocha MA, Mendes JB, Andrade SP. 2010. Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1. Biomed Pharmacother 64(1):29-34.
41. Ploeger HE, Takken T, de Greef MH, Timmons BW. 2009. The effects of acute and chronic exercise on inflammatory markers in children and adults with a chronic inflammatory disease: A systematic review. Exerc Immunol Rev 15:6-41.
42. Diegelmann RF, Cohen IK, Kaplan AM. 1981. The role of macrophages in wound repair: A review. Plast Reconstr Surg 68(1):107-113.
43. Gordon JS, Wolanin PM, Gonzalez AV, Fela DA, Sarngadharan G, Rouzard K, Perez E, Stock JB, Stock MB. 2008. Topical N-acetyl-S-farnesyl-L-cysteine inhibits mouse skin inflammation, and unlike dexamethasone, its effects are restricted to the application site. J Invest Dermatol 128(3):643-654.
44. Young JM, Wagner BM, Spires DA. 1983. Tachyphylaxis in 12-O-tetradecanoylphorbol acetate- and arachidonic acid-induced ear edema. J Invest Dermatol 80:48-52.
45. Rao TS, Currie JL, Shaffer AF, Isakson PC. 1993. Comparative evaluation of arachidonic acid (AA) and tetradecanoylphorbol acetate (TPA)-induced dermal inflammation. Inflammation 17(6):723-741.
46. Gewert K, Tapper H, Nauclér C, Sundler R. 1996. Dexamethasone downregulates lysosomal secretion in mouse macrophages: Involvement of signaling through protein kinase C. J Inflamm 47(3):115-125.
47. Yoshida M, Sakuma-Mochizuki J, Abe K, Arai T, Mori M, Goya S, Matsuoka H, Hayashi S, Kaneda Y, Kishimoto T. 1999. In vivo gene transfer of an extracellular domain of platelet-derived growth factor beta receptor by the HVJ-liposome method ameliorates bleomycin-induced pulmonary fibrosis. Biochem Biophys Res Commun 265:503-508.
48. McAnulty RJ, Laurent GJ. 1995. Pathogenesis of lung fibrosis and potential new therapeutic strategies. Exp Nephrol 3:96-107.
49. Khalil N, Bereznay O, Sporn M, Greenberg AH. 1989. Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med 170:727-737.
50. Maeda A, Hiyama K, Yamakido H. 1996. Increased expression of platelet-derived growth factor A and insulin-like growth factor-I in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice. Chest 109:780-786.
51. Dik WA, McAnulty RJ, Versnel MA, Naber BA, Zimmermann LJ, Laurent GJ, Mutsaers SE. 2003. Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats. Thorax 58:765-771.